207 related articles for article (PubMed ID: 20345715)
1. Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD.
Flood VH; Lederman CA; Wren JS; Christopherson PA; Friedman KD; Hoffmann RG; Montgomery RR
J Thromb Haemost; 2010 Jun; 8(6):1431-3. PubMed ID: 20345715
[No Abstract] [Full Text] [Related]
2. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
Michiels JJ; van Vliet HH
Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
[TBL] [Abstract][Full Text] [Related]
3. 2B or not 2B? What is the role of VWF in platelet-matrix interactions? And what is the role of the VWF:CB in VWD diagnostics? These are the questions.
Favaloro EJ
J Thromb Haemost; 2006 Apr; 4(4):892-4. PubMed ID: 16634760
[No Abstract] [Full Text] [Related]
4. Laboratory Testing for von Willebrand Factor Collagen Binding (VWF:CB).
Favaloro EJ; Mohammed S
Methods Mol Biol; 2017; 1646():417-433. PubMed ID: 28804845
[TBL] [Abstract][Full Text] [Related]
5. Novel Likely Pathogenic Variant in the A3 Domain of von Willebrand Factor Leading to a Collagen-Binding Defect.
Fels S; Boeckelmann D; Glonnegger H; Büchsel M; Zieger B
Hamostaseologie; 2023 Apr; 43(2):122-125. PubMed ID: 35104900
[TBL] [Abstract][Full Text] [Related]
6. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
7. Comparison of an automated chemiluminescent assay to a manual ELISA assay for determination of von Willebrand Factor collagen binding activity on VWD plasma patients previously diagnosed through molecular analysis of VWF.
Jousselme E; Jourdy Y; Rugeri L; Négrier C; Nougier C
Int J Lab Hematol; 2018 Feb; 40(1):77-83. PubMed ID: 28980759
[TBL] [Abstract][Full Text] [Related]
8. Collagen binding provides a sensitive screen for variant von Willebrand disease.
Flood VH; Gill JC; Friedman KD; Christopherson PA; Jacobi PM; Hoffmann RG; Montgomery RR; Haberichter SL;
Clin Chem; 2013 Apr; 59(4):684-91. PubMed ID: 23340442
[TBL] [Abstract][Full Text] [Related]
9. Molecular modeling of ligand and mutation sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand's disease.
Jenkins PV; Pasi KJ; Perkins SJ
Blood; 1998 Mar; 91(6):2032-44. PubMed ID: 9490688
[TBL] [Abstract][Full Text] [Related]
10. Von Willebrand factor collagen binding activity in the diagnosis of von Willebrand disease: an alternative to ristocetin co-factor activity?
Casonato A; Pontara E; Bertomoro A; Sartorello F; Cattini MG; Girolami A
Br J Haematol; 2001 Mar; 112(3):578-83. PubMed ID: 11260057
[TBL] [Abstract][Full Text] [Related]
11. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
[TBL] [Abstract][Full Text] [Related]
12. Performance and clinical utility of a commercial von Willebrand factor collagen binding assay for laboratory diagnosis of von Willebrand disease.
Popov J; Zhukov O; Ruden S; Zeschmann T; Sferruzza A; Sahud M
Clin Chem; 2006 Oct; 52(10):1965-7. PubMed ID: 16887898
[TBL] [Abstract][Full Text] [Related]
13. A comparative evaluation of a new fully automated assay for von Willebrand factor collagen binding activity to an established method.
Stufano F; Baronciani L; Mane-Padros D; Cozzi G; Faraudo S; Peyvandi F
Haemophilia; 2018 Jan; 24(1):156-161. PubMed ID: 29168270
[TBL] [Abstract][Full Text] [Related]
14. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis or Exclusion of von Willebrand Disease Using Laboratory Testing.
Favaloro EJ
Methods Mol Biol; 2017; 1646():391-402. PubMed ID: 28804843
[TBL] [Abstract][Full Text] [Related]
16. Utility of the von Willebrand factor collagen binding assay in the diagnosis of von Willebrand disease.
Favaloro EJ
Am J Hematol; 2017 Jan; 92(1):114-118. PubMed ID: 27622788
[TBL] [Abstract][Full Text] [Related]
17. Contribution of the collagen binding activity (VWF:CB) in the range of tests for the diagnosis and classification of von Willebrand disease.
Ferhat-Hamida MY; Boukerb H; Hariti G
Ann Biol Clin (Paris); 2015; 73(4):461-8. PubMed ID: 26411913
[TBL] [Abstract][Full Text] [Related]
18. Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease.
Baronciani L; Federici AB; Cozzi G; Canciani MT; Mannucci PM
J Thromb Haemost; 2007 Feb; 5(2):282-8. PubMed ID: 17155947
[TBL] [Abstract][Full Text] [Related]
19. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
20. N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
Lanke E; Kristoffersson AC; Isaksson C; Holmberg L; Lethagen S
Eur J Haematol; 2008 Nov; 81(5):384-90. PubMed ID: 18637125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
